Rokabio
Warren, US · 1 known investors
Roka Bio develops molecular pathogen detection assays that target ribosomal RNA (rRNA) for food pathogen testing. The technology provides fully automated, single-protocol assays with reduced enrichment times for food safety applications.
Founders & leadership
LB
Lars BoesgaardExecutive
PG
Paul G. ThomasExecutive
Board
JB
Jim Barret, PhDBoard director
FC
Fred CohenBoard director
JS
Jonathan SilversteinBoard director
DM
David McGirrBoard director
NV
Nicholas ValerianiBoard director
MP
Michael P. DoyleBoard director
Investors · 1
Reported raises · per SEC filings
Form D private placements$22.5M disclosed across 1 round · 2016
▶$22.5MraisedSep 2016 · 32 investors · BiotechnologyRule 506(b)
▶$22.5MraisedSep 2016 · 32 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Lars BoesgaardExecutive Officer
- David McGirrDirector
- Nicholas ValerianiDirector
- Jim Barret, PhDDirector
- Michael P. DoyleDirector
- Fred CohenDirector
- Jonathan SilversteinDirector
- Paul G. ThomasExecutive Officer, Director
- Offering amount
- $22.5M
- Amount sold
- $22.5M
- Sales commissions
- $949.9K
- Placement agents
- Roth Capital Partners, LLC
- First sale
- Sep 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Frequently asked questions
- What does Rokabio do?
- Roka Bio develops molecular pathogen detection assays that target ribosomal RNA (rRNA) for food pathogen testing. The technology provides fully automated, single-protocol assays with reduced enrichment times for food safety applications.
- Who are Rokabio's investors?
- Rokabio's investors include Aisling Capital.
- How much funding has Rokabio raised?
- Rokabio has disclosed $22.5M raised across 1 round.
- Where is Rokabio headquartered?
- Rokabio is headquartered in Warren, US.